Sage Journals: Discover world-class research

Retricted access

Research article

First published 2009-12

Efalizumab: What Went Wrong?

Douglas Bryant, Nedhal Ayoub

Journal of Psoriasis and Psoriatic Arthritis®

Retricted access

Research article

First published 2009-2

Serum Sickness–Like Reaction Associated with Efalizumab

Sadia Ashraf-Benson, Geoffrey C Wall, Lisa A Veach

Annals of Pharmacotherapy

Retricted access

Review article

First published 2005-9

Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis

Joseph K Jordan

Annals of Pharmacotherapy

Free access

Research article

First published 2008-4

Effect of Efalizumab on Neutrophil and Monocyte Functions in Patients with Psoriasis

F. Capsoni, A.M. Ongari, E. Frigerio [...]

International Journal of Immunopathology and Pharmacology

Retricted access

Research article

First published 2006-3

Efalizumab in the Treatment of Psoriasis

Aditya K. Gupta, Andréa M. Cherman

Journal of Cutaneous Medicine and Surgery

Retricted access

Research article

First published 2007-3

Efalizumab for the Treatment of Psoriatic Arthritis

Kim A. Papp, Ivor Caro, Hoi M. Leung [...]

Journal of Cutaneous Medicine and Surgery

Retricted access

Case report

First published 2009-3

Exacerbation of Psoriasis under Efalizumab Therapy

Efstathios Rallis, Constantinos Verros, Evmorfia Karanikola [...]

Journal of Cutaneous Medicine and Surgery

Retricted access

Research article

First published 2005-12

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

Kim A. Papp, Charles Camisa, Stephen P. Stone [...]

Journal of Cutaneous Medicine and Surgery

Retricted access

Research article

First published 2007-6

Safety and Tolerability of 60 Weeks' Extended Efalizumab Therapy in Patients with Chronic Moderate to Severe Plaque Psoriasis

Alice B. Gottlieb, Tiffani K. Hamilton, Ivor Caro [...]

Journal of Psoriasis and Psoriatic Arthritis®

Retricted access

Research article

First published 2003-5

Subcutaneously Administered Efalizumab (Anti-CD 11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis

Alice B. Gottlieb, Bruce Miller, Nicholas Lowe [...]

Journal of Cutaneous Medicine and Surgery

Search results